Appearing as a noteworthy development in the struggle against obesity, the drug is capturing considerable buzz. This treatment combines properties of two known GLP-1 binding agonists, liraglutide, with an additional glucose-dependent hormonal component. Early study data have indicated substantial weight loss in patients with a high BMI , perhap… Read More